Search research articles
Contact Us
Filters
Showing results (251-260 of 275) with videos related to
Page
of 28
Sort By:
Histopathology
|
April 15, 2020
Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial
Brett Delahunt, Judith D Murray, Allison Steigler, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 7, 2012
Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer
James W Denham, Chantelle Wilcox, David S Lamb, et al.
The Lancet. Oncology
|
November 16, 2012
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial
James W Denham, Chantelle Wilcox, David Joseph, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 19, 2023
Validation of prediction models for radiation-induced late rectal bleeding: Evidence from a large pooled population of prostate cancer patients
Alessandro Cicchetti, Claudio Fiorino, Martin A Ebert, et al.
Pathology
|
December 27, 2021
Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial
B Delahunt, A Steigler, C Atkinson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 23, 2011
MRI-guided prostate radiation therapy planning: Investigation of dosimetric accuracy of MRI-based dose planning
Jonathan Lambert, Peter B Greer, Fred Menk, et al.
The Lancet. Oncology
|
December 24, 2018
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial
James W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology
|
August 19, 2014
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial
James W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology
|
November 1, 2005
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial
James W Denham, Allison Steigler, David S Lamb, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 18, 2003
Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer
David S Lamb, James W Denham, Hedy Mameghan, et al.
Page
of 28
Search research articles
Search
Showing results (251-260 of 275) with videos related to
Sort By:
Page
of 28
Histopathology
|
April 15, 2020
Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial
Brett Delahunt, Judith D Murray, Allison Steigler, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 7, 2012
Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer
James W Denham, Chantelle Wilcox, David S Lamb, et al.
The Lancet. Oncology
|
November 16, 2012
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial
James W Denham, Chantelle Wilcox, David Joseph, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 19, 2023
Validation of prediction models for radiation-induced late rectal bleeding: Evidence from a large pooled population of prostate cancer patients
Alessandro Cicchetti, Claudio Fiorino, Martin A Ebert, et al.
Pathology
|
December 27, 2021
Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial
B Delahunt, A Steigler, C Atkinson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 23, 2011
MRI-guided prostate radiation therapy planning: Investigation of dosimetric accuracy of MRI-based dose planning
Jonathan Lambert, Peter B Greer, Fred Menk, et al.
The Lancet. Oncology
|
December 24, 2018
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial
James W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology
|
August 19, 2014
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial
James W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology
|
November 1, 2005
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial
James W Denham, Allison Steigler, David S Lamb, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 18, 2003
Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer
David S Lamb, James W Denham, Hedy Mameghan, et al.
Page
of 28